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Objective. To deﬁne the long-term (2–4 years) clinical and virological outcome of an antiretroviral treatment (ART) programme
in rural South Africa. Methods. We performed a retrospective observational cohort study, including 735 patients who initiated
ART. Biannual monitoring, including HIV-RNA testing, was performed. Primary endpoint was patient retention; virological
suppression (HIV-RNA < 50 copies/mL) and failure (HIV-RNA > 1000 copies/mL) were secondary endpoints. Moreover, possible
predictors of treatment failure were analyzed. Results. 63% of patients (466/735) have a fully suppressed HIV-RNA, a median of
three years after treatment initiation. Early mortality was high: 14% died within 3 months after treatment start. 16% of patients
experienced virological failure, but only 4% was switched to second-line ART. Male gender and a low performance score were
associatedwithtreatmentfailure;immunologicalfailurewasapoorpredictorofvirologicalfailure.Conclusions.An“allornothing”
phenomenon was observed in this rural South African ART programme: high early attrition, but good virological control in
those remaining in care. Continued eﬀorts are needed to enrol patients earlier. Furthermore, the observed viro-immunological
dissociation emphasises the need to make HIV-RNA testing more widely available.
1.Introduction
Sub-Saharan Africa houses most of the 33 million people
who are human immunodeﬁciency virus- (HIV-) infected
globally. The scale-up of antiretroviral treatment (ART)
roll-out that has taken place in this region over the last
decade is impressive. Consequently, an increasing number
of treatment-outcome data from African ART programmes
has been published. In spite of frequently observed high
early mortality rates, ART provides clear beneﬁts for most
HIV-infected patients. Typically, improvements in clinical,
immunological, and virological outcome measurements are
seen within months after starting treatment. However, long-
term data (more than one year of followup) are less readily
available [1, 2]. Moreover, most available data come from
urbanized areas, and for many ART programmes regular
HIV-RNA monitoring is not feasible. Clinical or immuno-
logical decline is frequently used to predict treatment failure
in low-income countries (LICs). However, several studies
portray limited correlation between such parameters and
virological failure [3–5]. Furthermore, recently it has been
shown that virological monitoring results in switching
treatment earlier and at higher CD4 counts [6].
Ndlovu Medical Centre (NMC) is located in rural South
Africa. Since the start of its ART programme, prospective
virological monitoring has been done for all patients.
Previously, we reported favourable short-term (one-year
followup) results of patients receiving ART at NMC [7].
The objective of this report was to describe the long-term
(2 to 4 years of followup) outcome. Due to consequent
monitoring, longitudinal virological data could be analyzed.
Furthermore, possible predictors for treatment failure were
analyzed.
2. Methods
2.1. Cohort Description and Data Collection. Ndlovu MC
is located in a poor, rural area of Limpopo, a province
in the northeast of the Republic of South Africa. Details2 AIDS Research and Treatment
on NMC and its ART programme have been described
elsewhere [7]. For the current study, all adults were included
who started ﬁrst-line ART at least 24 months before data-
collection. A WHO clinical stage IV and a CD4+ T-cell count
below 200cells/mm3 were used as criteria for treatment
eligibility. Treatment consisted of efavirenz or nevirapine
plus stavudine or zidovudine and lamivudine. In case of
virological failure, second-line ART was available. To this
end, a boosted protease inhibitor (PI, lopinavir/ritonavir)
was added to the nucleoside reverse transcriptase inhibitor
(NRTI) backbone.
Data were retrospectively collected from the medical
charts. Body mass indices (BMI, weight/height2)a r ec a l c u -
lated at each visit. CD4+ T-cell counts (FACSCount system,
Becton Dickinson Biosciences, San Jose, CA) and plasma
HIV-RNA levels (system 340 bDNA analyzer, Bayer AG,
Leverkusen, Germany, detection limit 50copies/mL) are
measuredbeforetreatmentinitiationandregularlythereafter
(four times in the ﬁrst and biannually during consecutive
years). Patients are seen by HIV-counsellors during each
clinic visit in order to provide information and to stimulate
treatment adherence.
2.2. Outcome Deﬁnitions. Patient retention-rate was deﬁned
by the proportion of patients remaining in care at NMC,
combined with the proportion of patients who were trans-
ferred to other clinics. Patient attrition was compiled of all-
cause mortality and people who were lost to followup.
Achieving an HIV-RNA below 50copies/mL was used
to deﬁne virological suppression. An HIV-RNA over
1000copies/mL after at least three months of ART was
considered to be an indicative of virological failure.
Patient attrition and virological failure were combined to
deﬁne treatment failure.
Immunological failure was deﬁned according to the
WHO guidelines as either (1) a CD4+ T-cell count after six
months of therapy below 100cells/mm3 or below the pre-
therapy count or (2) a 50% decline from the on-treatment
peak CD4+ T-cell count value [8].
2.3. Statistical Analysis. Patient retention-rate was the pri-
mary endpoint. Secondary outcomes were virological sup-
pression and treatment failure.
The negative and positive predictive values (NPV and
PPV, resp.) of immunological failure, to determine virolog-
ical failure, were calculated. Moreover, to deﬁne predictors
of treatment failure, we compared the distribution of several
determinants (Gender; Age; baseline BMI, CD4+ T-cell
count, Karnofsky score and log HIV-RNA; (N)NRTIs used;
employment status and years since treatment initiation)
between patients with treatment success and those experi-
encing treatment failure. To this end, all patients who started
ART were included in analyses. The same determinants were
used to deﬁne predictors of virological failure. In order to
minimize the inﬂuence of early mortality, only patients with
more than three-month followup were included in these
analyses.
Continuous data were compared with the Student’s t-
test or the paired t-test as appropriate. Proportions were
compared with the χ2 test, and data that were not normally
distributed were analyzed via the Mann-Whitney U or
Wilcoxon test. Kaplan-Meier survival analysis was used to
estimate the time from initiation of antiretroviral therapy to
virological suppression and the time from initial suppression
to subsequent virological failure. Odds ratios and 95%
conﬁdence intervals (95% CI) were calculated using logistic
regression analysis. The Cox proportional-hazards model
wasusedtoidentifyindependentpredictorsoftheendpoints.
To this end, determinants that were associated with the
outcome in univariate analysis (deﬁned as a P-value <.1)
were included in multivariate analysis. A P-value ≤.05 was
considered statistically signiﬁcant. Data were processed and
statistical analyses were done using SPSS version 15.
3. Results
3.1. Patient Characteristics. The ﬁrst 735 adults who started
ART at NMC were included in analysis. Median duration
between treatment initiation and data collection was 35
months (range 24–59). Women predominated (526/735,
72%). Unemployment rate was high at 70%; 24% of patients
had less than six years school attendance. The median
baseline CD4+ T-cell count (68cells/mm3, IQR 20–140) and
BMI (19.8kg/m2, IQR 17.4–23.0) demonstrate that many
patients were at an advanced stage of disease when initiating
treatment. Most individuals initially received a stavudine-
containing ART regimen (579/735, 79%); in 26% (151/579)
of those patients, stavudine was subsequently switched
to zidovudine, as they showed signs of neuropathy or
lipodystrophy. Efavirenz was the most commonly prescribed
NNRTI (58%. 426/735).
3.2. Clinical and Virological Outcome. Patient retention-rate
at end of followup was 65% (476/735). Most (429/476,
90%) of these patients were still in care and on treatment
at the NMC, but 10% (47/476) patients were transferred
out to other clinics. The remaining 35% (259/735) of
patients had either died or were lost to followup. Mortality
was the main cause for attrition (171/259, 66%). Attrition
typically occurred soon after treatment initiation; within
three months, one out of ﬁve persons was not in care
anymore (n = 152, Figure 1).
562/735 patients (76%) achieved virological suppression
on ﬁrst line ART. Suppression was established at a median of
12 weeks after treatment initiation. Not achieving virological
suppression was mainly due to early attrition (133/173, 77%
within three months after treatment start).
Longitudinal virological monitoring showed continued
virological control on ﬁrst-line ART in most patients
(466/735,63%).Thisproportionincreasedto80%(466/583)
if only those with more than 3-month followup were
included. Virological failure was observed in 117/735
patients (16%: 20%{117/583} of those with >3 months
followup). Median duration between initial response and
subsequent failure was 18 months. Only 4% (31/735) of all
patients who started ﬁrst-line ART were switched to second-
line ART. Most of them achieved virological suppressionAIDS Research and Treatment 3
after switching (25/31, 81%). Virological outcome data are
summarized in Figure 1.
Ongoing viral replication was limited in patients receiv-
ing ﬁrst-line ART. During complete followup, less than
10% of patients who remained in care had an HIV-RNA
>1000copies/mL and the vast majority of patients (71–
82%) showed complete, virological suppression (HIV-RNA
<50copies/mL, Figure 2).
3.3. Predictors of Failure. Ninety-ﬁve patients showed evi-
dence of immunological failure (13%). On the basis of
immunological parameters, virological failure would have
been missed in 66/117 patients (56%) and 44/95 patients
(46%) would mistakenly have been classiﬁed as experiencing
virological failure. Immunological failure therefore showed
a PPV and NPV for virological failure of 54% and 87%,
respectively.
Overall, treatment failure (attrition and/or virological
failure) occurred in 337 patients (46%) during followup. Of
allbaselinefactorsthatwereassociatedwithtreatmentfailure
in univariate analysis (low BMI and CD4+ T-cell count,
Karnofsky score ≤50, Zidovudine-use and gender), only a
low performance (Karnofsky) score (OR 3.6, 95% CI 1.8–
7.1) and male gender (OR 1.7, 95% CI 1.2–2.3) remained
independentlyassociatedwiththeoutcomeaftermultivariate
analysis (Table 1).
In patients with more than three-month followup,
baseline CD4+ T-cell count (P = .03) and age (P =
.07) were associated with virological failure in univariate
analysis. Neither remained independently associated with
this outcome after multivariate analysis.
4. Discussion
A median of three years after treatment initiation, half of
the patients receiving ART in this rural South African clinic
is still in care and has a fully suppressed HIV-RNA. Nearly
a quarter of patients died, mostly early on. Sixteen percent
of patients showed virological failure; only few of them
were switched to second-line treatment. Apart from a low
Karnofsky score at baseline, male gender was predictive of
treatment failure. The correlation between immunological
and virological failures on the other hand was minimal.
The high early mortality rate is probably largely
attributable to the advanced clinical stage patients are in
when seeking care, as has been described for other African
cohorts [1, 9]. Regression analysis indeed shows a low
performance score to be associated with treatment failure.
Thus, continued eﬀorts are needed to enrol patients earlier,
before clinical illness becomes evident. Male gender also
remained as an independent predictor of treatment failure
in our analysis. Similar associations have been observed
previously [10, 11], but others did not ﬁnd gender to be
of inﬂuence on ART outcome [12, 13]. In contrast, the
CD4+ T-cell count did not remain signiﬁcantly associated
with treatment failure, suggesting that starting ART prior to
clinical illness is of greater importance than merely avoiding
al o wC D 4 +T - c e l lc o u n t .
Table 1: Predictors of treatment failure.
Determinant
Treatment
Success∗
n = 398
Treatment
Failure∗∗
n = 337
Univariate
(P-value)
Multivariate
(P-value)
Male gender
n (%) 95 (24) 114 (34) <. 01 .01
Mean Age
(years) 35.33 5 .31 .0—
Mean BMI
(kg/m2) 21.11 9 .9 <. 01 .4
Karnofsky
score
≤50 n (%)
12 (3) 35 (11) <. 01 <. 01
Median CD4
(cells/mm3) 84 54 <. 01 .2
Mean 10log
HIV-RNA 4.94 .9 .8—
Time since start
ART n (%) .3—
(i) 2-3 years 217 (55) 162 (48)
(ii) 3-4 years 121 (30) 111 (33)
(iii) >4 years 60 (15) 60 (18)
Efavirenz use
n (%) 223 (56) 204 (61) .2—
Stavudine use
n (%) 324 (82) 253 (76) .05 .3
Unemployed
n (%) 275 (74) 237 (79) .1—
Treatment success∗ patients who remained in care during followup and
showed a good, virological response. Treatment failure∗∗: a combined
endpoint of patient attrition and virological failure. n: number of patients.
%: percentage of patients. BMI: body-mass index. CD4: CD4+ T-cell count.
ART: antiretroviral treatment.
Drug-resistance development is a major concern when
treating HIV. The virus can select drug-resistance mutations
in the presence of suboptimal drug levels. In case of
continued ART use in spite of ongoing viral replication,
accumulation of resistance can occur [14–16]. Mortality
was the main cause of treatment failure in our cohort.
In addition, continued virological control was observed in
the majority of patients who did remain in care. Due to
this observed “all or nothing” phenomenon, the number of
people experiencing ongoing viral replication in thepresence
of ART was limited.
Regular HIV-RNA testing is not feasible in many LICs.
In accordance with WHO-guidelines, treatment changes are
frequently based on immunological criteria alone [8, 17].
Immunological failure was a poor predictor for experiencing
virological failure in our cohort. Basing treatment decisions
on immunological parameters would lead to unnecessary
treatment switches in a substantial number of patients, as
has been described previously [4, 5]. We however show,
that the proportion of patients that would mistakenly
continueafailingregimeniftreatmentdecisionsweremerely
based on immunological parameters is even larger. Such
viro-immunological dissociation highlights the need for
virological monitoring for all patients receiving ART.4 AIDS Research and Treatment
• 104/152 (68%) died
• 8/152 (5%) transferred out
• 405/583 (69%) complete suppressiona
• 26/583 (4%) low viral replicationb
Virological failurec
on 2nd line ART
No data available
after switch
Viral suppressiona
on 2nd line ART
ART: antiretroviral therapy, Mo: months
b: HIV-RNA <50copies/mL and >1x blip∗
c: HIV-RNA >1000copies/mL after initial viral suppression
∗: “viral blip” deﬁned as HIV-RNA >50, but <1000copies/mL
735patientsinitiatedﬁrst-lineART
80%(466/583)hadagoodvirologicalresponse
4/31 (13%)
• 34/583 (6%) did not reach viral suppression
• 52/583 (9%) virological failurec;n oA R Ts w i t c h
• 31/583 (5%) virological failurec;s t a r t2nd-line ART
2/31 (6%) 25/31 (81%)
a: HIV-RNA <50copies/mL and ≤1x viral blip∗
20% (117/583) experienced virological failurec
152/735(21%)≤3Mofollowup
• 35/583 (6%) resuppression after extra counseling
• 40/152 (26%) lost to followup
583 with >3 Mofollowup
Figure 1: Virological treatment outcome.
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Figure 2: Viral replication during 1st line ART.
In the current study, regular (bi-annual) virological
monitoring was performed. Still, a substantial number of
patients continued their ﬁrst-line ART after showing the ﬁrst
evidence of virological failure. The delay between virological
failure and treatment switch is probably due to care-givers
focusing on extra adherence counselling, prior to switching
to the only available second-line regimen. On the basis of
virologicalfailurealone,16%ofpatientsinourcohorthadan
indication for a treatment switch. A recent review reported
nearly twice as many patients in low and middle income
countries needing a second-line regimen (26–32%, [17]),
but others reported similar numbers to those observed in
our cohort [18–20]. As most patients on second-line ART
achievedvirologicalsuppressionagain,thenumberofpeople
with ongoing viral replication may be reduced even further if
treatment switches are made earlier. However, future cost-
beneﬁt analyses will have to determine the optimal time to
switch.
There are some limitations to our study. Diagnostics for
underlying illnesses and documentation of adverse events
were limited. Causes of attrition were therefore generally
unknown. Moreover, due to the retrospective nature of our
study, bias due to unmeasured determinants cannot be ruled
out.
In conclusion, in this rural South African ART pro-
gramme with access to virological monitoring, early attrition
was the main cause for treatment failure. Virological failure
was limited in those remaining in care. Continued eﬀorts are
needed to enrol patients earlier into care. Furthermore, the
observed viro-immunological dissociation emphasises the
need to make HIV-RNA testing more widely available.AIDS Research and Treatment 5
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